VVD-849 is a RAS ligand. VVD-849 binds covalently to cysteine 242 in the RAS binding domain of PI3K p110α and promotes RAS/PI3K interaction. VVD-849 partially inhibits pAKT(S473) in HER2 over-expressing tumors. VVD-849 can be used cancers like breast cancer research.

SDZ 208-912 is a dual-action 5-HT1A/2 receptor agonist and dopamine D1 receptor antagonist. SDZ 208-912 exhibits partial dopamine agonism and atypical neurosedative effects in rodent models. SDZ 208-912 can be used in research on neurological disorders such as schizophrenia.

Lergotrile is a potent and orally active dopamine agonist and a prolactin secretion inhibitor. Lergotrile inhibits prolactin release from pituitaries by activating an adenohypophyseal dopamine receptor. Lergotrile has the potential for the research of Parkinson's disease.

PKRA83 (PKRA7) hydrochloride is a potent, blood-brain-penetrating PK2 antagonist that competes for PK2 binding to its receptors, PKR1 and PKR2. PKRA83 hydrochloride potently inhibits PK2 receptors with IC50 values of 5.0 nM and 8.2 nM for PKR1 and PKR2, respectively. PKRA83 hydrochloride exhibits anticancer, antiarthritis, and antiangiogenic activities.

SD 8381 is a potent and selective COX-2 inhibitor. SD 8381 shows IC50 values of 0.0098 μM for hCOX-2 and 0.69 μM for hCOX-1.

Repunapanor (compound 123) is a potent Na+/H+ exchanger 3 (NHE-3) inhibitor.

FTO ligand-1 is a FTO ligand for FTO PROTAC degrader FP54. FTO ligand-1 can inhibit cell proliferation and block the FP54-induced FTO degradation. FTO ligand-1 can be used for research of cancer, such as acute myeloid leukemia (AML).

Tilivapram (AVE8112) is an orally active PDE4 inhibitor. Tilivapram can regulate neurophysiological activities and improve cognitive and memory impairments. Tilivapram can be used in the research of various neuropsychiatric disorders such as schizophrenia and Parkinson's disease.

TK-684 is a potent and selective allosteric SHP2 inhibitor with IC50 values of 2.1, ＞1000 nM for SHP2WT, SHP22PTP, respectively. TK-684 inhibits cell proliferation and induces apoptosis. TK-684 decreases the protein expression of p-AKT, p-ERK.

KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer.

CS47 is a reversible Thioredoxin reductase 1 (TrxR1) inhibitor. CS47 activates stress-responsive GSH and iron regulatory programs, depleting GSH and promoting HO-1 overexpression and intracellular iron overload by ROS accumulation, and finally inducing ferroptosis in KRAS-independent lung cancers. CS47 has an anticancer activity with low cytotoxicity toward normal lung fibroblasts.

F 2833 is a lipid-lowering agent. F 2833 can reduce the levels of cholesterol, triglycerides, and plasma phospholipids. F 2833 can be used for research on diseases such as hyperlipidemia.

TK-685 is an orally active, selective, and allosteric SHP2 inhibitor with an IC50 of 2.1 nM. TK-685 inhibits esophageal cancer cell proliferation and induced apoptosis by targeting SHP2-mediated AKT and ERK signaling pathways.

Raxlaprazine etomoxil is a small molecule compound with dopamine D2 and D3 receptor modulating activity, which has potential application value in research related to mental illnesses. Raxlaprazine etomoxil exhibits high affinity for human recombinant D2L receptors, with an inhibition constant (Ki) of 1.95 nM. Raxlaprazine etomoxil effectively inhibits forskolin-stimulated cAMP accumulation, with an half maximal effective concentration (EC50) of 3.72 nM in functional activity experiments.

HBI-2375 (HYBI-084) is a selective, brain-penetrant and orally active MLL1-WDR5 interaction inhibitor. HBI-2375 inhibits WDR5 with an IC50 of 4.48 nM. HBI-2375 shows inhibition of proliferation in MV4;11 leukemia cells (IC50: 3.17 µM). HBI-2375 is capable of targeted disruption of histone methyltransferase activity in cancer cells. HBI-2375 can be used for the study of leukemia, glioma and glioblastoma.

RWJ-68022 (Example 9) is a cyclopentene derivative and a motilin receptor antagonist. RWJ-68022 can compete with motilin and erythromycin for the motilin receptor site. RWJ-68022 can be used in the research of gastrointestinal-related diseases.

IMB-881 is an antibacterial agent. IMB-881 binds to LptA to inhibit the interaction between LptA and LptC. IMB-881 shows potent antibacterial activity against Gram-negative bacteria.

GZD-257 is a brain-penetrant, ATP-competitive FAK inhibitor (IC50 = 14.3 nM), performing 4.77-fold selectivity with FAK to Pyk2 (IC50 = 68.2 nM). GZD-257 can significantly induce apoptosis of U118MG cells and arrest the cell cycle at the G2/M phase. GZD-257 can be used for the study of Glioblastoma (GBM).

AGU661 is a Microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitor with an IC50 of 0.22  nM. AGU661 lowers PGE2 formation in human pro-inflammatory M1 macrophages and activated monocytes without affecting other lipid mediator pathways. AGU661 has unfavorable physicochemical properties with poor metabolic stability and strong plasma protein binding tendencies. AGU661 into PLGA-based NPs significantly enhances its bioactivity. AGU661 can be used for inflammatory disorders research.

POI ligand-2 is a ligand for GPX4 protein. POI ligand-2 can be used to synthesize PROTAC, such as PROTAC GPX4 degrader-5.

SRI-22136 is a Delta Opioid Receptor (DOR) antagonist that can cross blood-brain barrier with a IC50 of 0.42 nM. SRI-22136 does not have agonistic activity but antagonistic activity against DOR, MOR (IC50 = 370 nM), KOR (IC50 = 54 nM) and can avoid addiction/aversion effects. SRI-22136 can effectively inhibit the BACE1 activity induced by DADLE (a DOR agonist)) (IC50 = 120 nM). SRI-22136 prevents completely Alzheimer’s-like pathology in mouse model. SRI-22136 can used for the study of Alzheimer’s disease.

NC-1175 (hydrochloride) is an antifungal agent targeting cell membrane H+-ATPase. NC-1175 (hydrochloride) can be used for the research of infection.

STING ligand-4 (Compound 2) is a nitro-free covalent STING inhibitor with an IC50 < 0.2 μM. STING ligand-4 can be used for synthesis of PROTAC STING degrader-4.

BCL6 ligand-4 is an BCL6 ligand that can be used in the synthesis of PROTACs, such as BCL6 PROTAC 1.

ONO-1714 is an orally active nitric oxide synthase inhibitor. ONO-1714 attenuates endotoxin-induced acute lung injury, reduces intestinal ischemia–reperfusion injury, represses biliary carcinogenesis.

SC-42867 is a PGE2 antagonist. SC-42867 can be metabolized in the liver through oxidative N-dealkylation, aromatic hydroxylation, and binding reactions. SC-42867 can be used for research on metabolic conditions.

SS-750 is an orally active Triazole derivative and antifungal agent. SS-750 binds to fungal cytochrome P450. SS-750 shows antifungal activities against Candida species and C. neoformans strains tested. SS750 shows MIC90 values of 0.25, 1, and 2 μg/mL against Candida parapsilosis, C. krusei, and C. glabrata, respectively. SS-750 improves systemic and pulmonary candidiasis caused by C. albicans.

RS-79948-197 hemihydrate is a non-imidazoline α2-adrenoceptor antagonist. RS-79948-197 hemihydrate shows Kd values of 0.42 nM, 0.18 nM, 0.19 nM, 0.60 nM, 0.46 nM, and 0.77 nM for rat α2A, rat α2B, rat α2C, human α2A, human α2B, and human α2C, respectively.

MolPort-010-778-422 is a high-affinity inhibitor targeting the ACE2 receptor of SARS-CoV-2 virus. MolPort-010-778-422 demonstrates excellent antiviral activity (IC50=8.9 nM). MolPort-010-778-422 is promising for research of SARS-CoV-2.

APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research.